The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by KELLNER, M.
* Articles by WIEDEMANN, K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by KELLNER, M.
* Articles by WIEDEMANN, K.
Related Collections
* Panic Disorder
* Posttraumatic Stress Disorder
Am J Psychiatry 155:1299, September 1998
©Copyright 1998 American Psychiatric Association


Letter to the Editor

Provocation of a Posttraumatic Flashback by Cholecystokinin Tetrapeptide?

MICHAEL KELLNER, M.D, ROBERT LEVENGOOD, M.D., RACHEL YEHUDA, PH.D.
New York, N.Y., and KLAUS WIEDEMANN, M.D.
Hamburg, Germany

To the Editor: Among the intrusive symptoms of posttraumatic stress disorder (PTSD), flashbacks represent a still poorly understood phenomenon. Some symptomatic aspects of flashbacks closely resemble panic attacks; experimental paradigms of panic provocation, such as sodium lactate (1, 2) and yohimbine (3), have also been reported to provoke flashbacks in PTSD patients, even without comorbid panic disorder. We report our observation of the first PTSD patient to receive an intravenous bolus of 50 mg of the potent panicogen cholecystokinin tetrapeptide (CCK-4) (4) in a double-blind, placebo-controlled randomized trial. Written informed consent was obtained from the patient, and the protocol was approved by the institutional review board.

Mr. A, a 35-year-old African American, has been suffering from chronic PTSD (DSM-IV) with repetitive flashbacks for 4 years after being shot in the stomach point-blank. The Structured Clinical Interview for DSM-IV showed a remitted alcohol dependence but no other axis I comorbidity. After placebo injection, no significant symptoms emerged. After injection of CCK-4, Mr. A developed a full-blown panic attack (DSM-IV criteria) with nausea and abdominal symptoms. Furthermore, he reported 1) having seen himself, as though in a video, back in the posttrauma emergency room; 2) having smelled blood; and 3) having felt a drainage in his stomach for about 45 seconds, beginning approximately 1 minute after the injection of CCK-4.

This flashback occurring during a CCK-4-induced panic attack, could have been a drug effect mediated by the activation of brainstem CCK-B receptors (4). On the other hand, Mr. A's abdominal symptoms produced by CCK-4 and his contingent memories of the trauma could have acted as conditioned stimuli to trigger his flashback. In addition, the hospital environment's possible facilitating role for a flashback to an emergency room needs to be kept in mind (1). Of course, a spontaneous or factitious flashback cannot be definitely excluded. Further experiments with CCK-4 to assess the role of CCK-B receptors in the pathophysiology of posttraumatic flashbacks and symptoms of anxiety in patients suffering from PTSD are promising.

REFERENCES

  1. Rainey JM, Aleem A, Ortiz A, Yeragani V, Pohl R, Berchou R: A laboratory procedure for the induction of flashbacks. Am J Psychiatry 1987; 144:1317–1319 [Abstract/Free Full Text]
  2. Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin D, Wilkinson CW, Raskind MA: Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Am J Psychiatry 1997; 154:266–268 [Abstract]
  3. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS: Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:266–274[Abstract]
  4. Harro J, Vasar E, Bradwejn J: CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14:244–249[Medline]



This article has been cited by other articles:


Home page
J Clin PharmacolHome page
C.-Y. Wang, Z.-J. Zhang,, W.-B. Li, Y.-M. Zhai, Z.-J. Cai, Y.-Z. Weng, R.-H. Zhu, J.-P. Zhao, and H.-H. Zhou
The Differential Effects of Steady-State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers
J. Clin. Pharmacol., July 1, 2004; 44(7): 785 - 792.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
A. K. ASHTON
Olanzapine Augmentation for Trichotillomania
Am J Psychiatry, November 1, 2001; 158(11): 1929 - 1930.
[Full Text]


This Article
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by KELLNER, M.
* Articles by WIEDEMANN, K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by KELLNER, M.
* Articles by WIEDEMANN, K.
Related Collections
* Panic Disorder
* Posttraumatic Stress Disorder


Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org